



BlueCross BlueShield  
of Alabama

---

**Name of Blue Advantage Policy:**

**Dopamine Transporter Imaging with Single Photon Emission  
Computed Tomography (DAT-SPECT)**

Policy #: 504

Latest Review Date: November 2024

Category: Radiology

---

**BACKGROUND:**

*Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:*

1. *Safe and effective;*
2. *Not experimental or investigational\*;*
3. *Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is:*
  - *Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member;*
  - *Furnished in a setting appropriate to the patient's medical needs and condition;*
  - *Ordered and furnished by qualified personnel;*
  - *One that meets, but does not exceed, the patient's medical need; and*
  - *At least as beneficial as an existing and available medically appropriate alternative.*

*\*Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill **Original Medicare** for covered services that are related to **clinical trials** that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).*

## **POLICY:**

### **Effective for dates of service on or after October 9, 2020:**

**Blue Advantage** will treat **dopamine transporter imaging with single photon emission computed tomography (DaT-SPECT)** as a **covered benefit** when used for individuals with:

- clinically uncertain Parkinson disease (PD); **OR**
- clinically uncertain dementia with Lewy bodies

**Blue Advantage** will treat the use of **dopamine transporter imaging with single-photon emission computed tomography** as a **non-covered benefit** and as **investigational** for all other indications not included above.

**Note:** In July 2021, aducanumab (Aduhelm™; Biogen), received FDA accelerated approval and in July 2023, lecanemab-irmb- (Leqembi; Esai) received FDA approval as amyloid beta-targeted antibodies was approved for the treatment of mild cognitive impairment or mild dementia due to Alzheimer disease. The safety and efficacy of aducanumab or lecanemab in individuals with dementia with Lewy bodies has not been established as participants with any medical or neurological condition other than Alzheimer disease that might be a contributing cause to the subject's cognitive impairment were excluded from trials. The use of dopamine transporter imaging with single-photon emission computed tomography for the diagnosis, management, or surveillance of Alzheimer disease is considered out of scope for this policy.

*Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.*

## **DESCRIPTION OF PROCEDURE OR SERVICE:**

Dopamine transporter imaging with single-photon emission computed tomography (DaT-SPECT), using radiopharmaceutical ioflupane injection, is a neuro-imaging modality being evaluated to improve the differential diagnosis of parkinsonian syndromes from non-parkinsonian tremor, as well as dementia with Lewy bodies from Alzheimer disease.

### **Parkinsonian Syndromes**

Parkinsonian Syndromes are a group of diseases that share similar cardinal signs, characterized by bradykinesia, rigidity, resting tremor, and gait disturbance. Parkinson disease (PD) is the most common cause of Parkinsonism.

Despite the well-known symptoms of PD, diagnosis is challenging even for experienced clinicians, particularly in early stages of the disease. In addition, other etiologies such as

essential tremor, corticobasal degeneration, multisystem atrophy, progressive supranuclear palsy, vascular parkinsonism, and drug-induced parkinsonism can lead to a similar set of symptoms.

One recent approach to improve the accuracy of clinical diagnosis of PD and other parkinsonian syndromes is to evaluate the integrity of dopaminergic pathways in the brain using DaT-SPECT imaging.

### **Dementia with Lewy Bodies**

Dementia with Lewy Bodies (DLB) is a type of dementia characterized by Parkinsonism, visual hallucinations, cognitive fluctuation, sleep disorders, and severe neuroleptic sensitivity. DLB is the second most common form of degenerative dementia; Alzheimer disease, which can have similar symptoms at onset, is the most common.

Diagnosis can be challenging, particularly when individuals have multiple comorbidities including cerebrovascular disease and/or Alzheimer disease. As with PD, DLB is characterized by the degeneration of nigrostriatal neurons; as such, DaT-SPECT is also proposed to differentiate DLB from Alzheimer disease.

### **Dopamine Transporter Imaging With Single-Photon Emission Computed Tomography (DaT-SPECT)**

Dopamine transporter imaging with single-photon emission computed tomography (DaT-SPECT) is based on the selective affinity of dopamine transporter ligands for dopamine synthesizing neurons, which allows visualization of deficits in the nigrostriatal dopaminergic pathway.

Dopamine transporter ligands include iodine 123 2 $\beta$ -carbomethoxy-3 $\beta$ -(4-iodophenyl) tropane (123 I- $\beta$ -CIT), which is a cocaine analogue with affinity for both dopamine transporter and serotonin transporters. Intravenous 123I- $\beta$ -CIT requires a delay between injection and scan of about 24 hours. Iodine 123 N-(3-fluoropropyl)-2 $\beta$ -carbomethoxy-3 $\beta$ -(4-iodophenyl) nortropane (123I-FP-CIT) is a fluoropropyl derivate of  $\beta$ -CIT that is selective for brain striatal dopamine transporter, but can also bind to the serotonin transporter. Intravenous 123I-FP-CIT can be injected three to six hours before the scan (DaTscan). Other ligands with affinity for dopamine transporter include technetium 99m (2 $\beta$  ((N, N'-bis (2-mercaptoethyl) ethylene diamino) methyl) and 3 $\beta$ -(4-chlorophenyl) tropane (99mTc-TRODAT-1).

Binding of ligands with an affinity for DaT ligands in the striatum is, in general, reduced in PD, genetic parkinsonism, DLB, corticobasal degeneration, progressive supranuclear palsy, and multiple system atrophy. In contrast, striatal DaT ligand binding is expected to be within the normal range of Alzheimer disease, essential tremor, dystonic tremor, orthostatic tremor, drug-induced parkinsonism, and psychogenic parkinsonism.

Visualization of striatal dopamine transporter binding, through DaT-SPECT, permits assessment of presynaptic dopaminergic deficit. It is proposed that an abnormal DaT-SPECT scan supports the diagnosis of PD, DLB, or other neurodegenerative parkinsonian syndromes, while a normal DaT-SPECT scan in a symptomatic individual supports the diagnosis of a disease not affecting the nigrostriatal dopaminergic pathway.

Analysis of DaT-SPECT images can be visual, semiquantitative, or quantitative. In individuals with PD, physical symptoms start after 30% to 50% of dopaminergic neurons have degenerated. Symptomatic individuals would be thus expected to have sufficient abnormality on DaT-SPECT for visual analysis to be adequate for interpretation. A variety of methods are being tested to improve the validity and reliability of ratings, including commercially available software to define the region of interest for analysis and the development of an atlas for visual interpretation. Several research centers are developing quantitative and semiquantitative classification methods for the evaluation of DaT-SPECT images.

Anatomic variation in the brain, including vascular lesions, may impede the distribution of the iodine-123 tracer and could result in an abnormal scan. Dopamine agonists and levodopa may also affect DaT expression, which could influence the ability of DaT-SPECT to monitor the progression of disease unless these agents are discontinued prior to imaging. Individuals with clinically diagnosed PD or DLB, who present with a normal DaT-SPECT scan, are referred to in the literature as having “scans without evidence of dopaminergic deficit.” While many of these individuals are ultimately diagnosed with non-PD syndromes, a portion of individuals with normal DaT-SPECT imaging are confirmed to have PD or DLB by the reference standard. In studies where clinical diagnosis is used as an end point, scans without evidence of dopaminergic deficit are present in 3% to 20% of PD individuals. In a study of individuals clinically diagnosed with DLB, van der Zande et al (2016) found that 10% of these individuals had normal scans. Further research may shed light on these cases.

## **KEY POINTS:**

The most recent literature review was updated through August 26, 2024.

### **Summary of Evidence**

For individuals who have clinically uncertain Parkinson disease (PD) who receive dopamine transporter imaging with single-photon emission computed tomography (DaT-SPECT), the published evidence includes randomized controlled trials (RCTs), cohort studies, and case series. Relevant outcomes are symptoms, functional outcomes, and treatment-related mortality and morbidity. In populations with clinically apparent PD, studies of diagnostic accuracy have reported high sensitivity and specificity for PD. Studies of clinical validity in the target population of clinically uncertain PD are limited by gaps in study design, conduct, and relevance. Evidence on clinical utility in the target population includes an RCT showing no significant difference in outcomes over time between individuals who received a DaT-SPECT scan and those who did not.

For individuals who have clinically uncertain dementia with Lewy bodies who receive DaT-SPECT, the published evidence includes RCTs, cohort studies, and case series. Relevant outcomes are symptoms, functional outcomes, and treatment-related mortality and morbidity. No such studies with the optimal reference standard to assess clinical validity have been performed in the target population of clinically uncertain dementia with Lewy bodies. No studies have directly evaluated the effect of DaT-SPECT on health outcomes in the target population.

## **Clinical Input from Physician Specialty Societies and Academic Medical Centers**

### **2018 Input**

Clinical input was sought to help determine whether the use of DaT-SPECT in individuals with clinically uncertain Parkinson disease or clinically uncertain dementia with Lewy bodies would provide a clinically meaningful improvement in net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, clinical input was received from three respondents, including one specialty society-level response and two physician-level responses identified through specialty societies.

In individuals who have clinically uncertain PD who receive DaT-SPECT, clinical input supports that DaT-SPECT is clinically useful when a negative result on DaT-SPECT is used to inform treatment decisions by reducing or avoiding unnecessary dopaminergic therapy. Clinical input highlights that the published RCT also reported changes in management following DaT-SPECT imaging that may translate to improvements in health outcomes over time, and the one-year study follow-up may be too short to demonstrate significant improvement in quality of life in a slowly progressive disease such as PD. Clinical input further supports that DaT-SPECT offers clinically valid diagnostic information about the presence or absence of functional loss in the dopamine system (ie, nigrostriatal degeneration) and is clinically useful for clinically uncertain Parkinson syndrome when a negative result on DaT-SPECT is used to inform treatment decisions by reducing or avoiding unnecessary dopaminergic therapy in individuals who have clinically uncertain dementia with Lewy bodies who receive DaT-SPECT, clinical input supports that DaT-SPECT is clinically useful when a positive result on DaT-SPECT is used to inform treatment decisions by avoiding potentially harmful use of neuroleptics which may be used in dementia individuals. Clinical input noted that DaT-SPECT offers clinically valid diagnostic information about the presence or absence of functional loss in the dopamine system (i.e., nigrostriatal degeneration) and is clinically useful for clinically uncertain dementia with Lewy bodies using a chain of evidence where a positive result on DaT-SPECT is used to inform treatment decisions by avoiding potentially harmful use of neuroleptics typically used in dementia individuals.

## **Practice Guidelines and Position Statements**

### **American College of Radiology**

In 2019, the American College of Radiology updated the appropriateness criteria for movement disorders and neurodegenerative diseases. The College categorized Ioflupane SPECT/CT as 'may be appropriate' for initial imaging of Parkinsonian syndrome. A strength of evidence rating was not given for this statement.

The American College of Radiology (2019) updated the appropriateness criteria for dementia. The College categorized Ioflupane SPECT or SPECT/CT brain as 'may be appropriate' for initial imaging for suspected dementia with Lewy bodies. A strength of evidence rating was not given for this statement.

### **Dementia of Lewy Bodies Consortium**

In 2017, the Dementia of Lewy Bodies Consortium published clinical guidelines on diagnosis and management based on American expert opinion. The guidelines stated that reduced DaT uptake in basal ganglia demonstrated by SPECT is an indicative biomarker. As such, dementia

with abnormal DaT-SPECT imaging would be classified as possible dementia with Lewy bodies. The presence of another core clinical feature (fluctuating cognition, recurrent visual hallucinations, rapid-eye-movement sleep disorder, parkinsonism motor abnormalities) in addition to dementia and abnormal DaT-SPECT imaging would allow classification as probable dementia with Lewy bodies. It was noted that individuals with autopsy-confirmed dementia with Lewy bodies may have normal DaT-SPECT imaging.

### **Movement Disorder Society**

In 2015, the Movement Disorder Society's (MDS) published diagnostic criteria for PD intended for use in clinical research but also commonly used to guide clinical diagnosis. The MDS considers the clinical expert opinion to be the criterion standard to diagnose PD and that diagnoses are usually made clinically without need for ancillary diagnostic testing. Methods that may become available as knowledge advances are diagnostic biochemical markers, anatomic neuroimaging, and methods to detect alpha-synuclein deposition. MDS noted that, although dopaminergic neuroimaging can help to distinguish parkinsonism from PD mimics like essential tremor, "it does not qualify as a criterion for the differentiation of PD from other parkinsonian conditions like atypical parkinsonian syndromes." In 2023, the MDS published a statement on the biological definition, staging and classification of PD. The document mentions dopamine imaging but states that its use is not widespread enough to be included in a staging or classification schema.

### **National Institute for Health and Care Excellence**

The National Institute for Health and Care Excellence published guidance on the diagnosis and management of PD in 2006, which was updated in 2017. The 2006 guidance stated that 123I-FP-CIT SPECT should be considered for people with tremor where essential tremor cannot be clinically differentiated from parkinsonism (based on studies with level of evidence 1a or 1b); this guidance is continued in 2017 recommendations. In addition, the 2006 guidance stated that 123I-FP-CIT SPECT should be available to specialists with expertise in its use and interpretation (based on level of evidence IV, expert opinion).

The Institute updated its guidance on dementia in 2018. It recommended that 123I-FP-CIT SPECT be used to help establish the diagnosis in those with suspected DLB [dementia with Lewy bodies] if the diagnosis is uncertain.

### **Society of Nuclear Medicine and Molecular Imaging et al**

In 2020, the Society of Nuclear Medicine and Imaging and the European Association of Nuclear Medicine published a joint practice guideline and procedure standard for dopaminergic imaging in Parkinsonian syndromes. The guideline indicated presynaptic dopaminergic imaging for "detecting loss of nigrostriatal dopaminergic neuron terminals of individuals with parkinsonian syndromes, especially:

- To support the differential diagnosis between essential tremor and neurodegenerative parkinsonian syndromes. Note that presynaptic dopaminergic imaging is unable to distinguish IPD [idiopathic Parkinson disease] and DLB from PSP [progressive supranuclear palsy], CBD [corticobasal degeneration], or putaminal variant of MSA [multiple system atrophy];

- To help distinguish between dementia with Lewy bodies and other dementias (in particular, Alzheimer’s disease, AD);
- To support the differential diagnosis between parkinsonism due to presynaptic degenerative dopamine deficiency and other forms of parkinsonism, e.g., between IPD and drug-induced, psychogenic, or vascular parkinsonism;
- To detect early presynaptic parkinsonian syndromes."

In 2011, the Society of Nuclear Medicine, now called the Society of Nuclear Medicine and Molecular Imaging, provided practice guidelines for DaT-SPECT. The guidelines stated that the main indication for DaT-SPECT is striatal DaT visualization in the evaluation of adults with suspected parkinsonian syndromes to help differentiate essential tremor from tremor due to presynaptic parkinsonian syndromes (PD, multisystem atrophy, progressive supranuclear palsy). Other indications are the early diagnosis of presynaptic parkinsonian syndromes, differentiation of presynaptic parkinsonian syndromes from parkinsonism without a presynaptic dopaminergic loss (e.g., drug-induced parkinsonism, psychogenic parkinsonism), and differentiation of dementia with Lewy bodies from AD. The guidance stated that visual interpretation of the scan is usually sufficient for clinical evaluation, where the striatal shape, extent, symmetry, and intensity differentiate normal from abnormal. For semiquantitative analysis, each site should establish its own reference range by scanning a population of healthy controls or by calibrating its procedure with another center that has a reference database.

**U.S. Preventative Service Task Force Recommendations**

Not applicable

**KEY WORDS:**

DaTscan, DAT-SPECT, 123I-Ioflupane, Iodine I-123 ioflupane diagnostic study, dopamine transporter SPECT using 123I-Ioflupane, FP-CIT SPECT, [123I]-FP-CIT SPECT imaging

**APPROVED BY GOVERNING BODIES:**

In 2011, DaTscan™ (GE Healthcare, Chicago, IL) was approved by the U.S. Food Drug Administration through a new drug application and is “indicated for striatal dopamine transporter visualization using single photon emission computed tomography brain imaging to assist in the evaluation of adult individuals with suspected parkinsonian syndromes. In these individuals, DaTscan may be used to help differentiate ET [essential tremor] from tremor due to parkinsonian syndromes (idiopathic Parkinson's disease, multiple system atrophy and progressive supranuclear palsy). DaTscan is an adjunct to other diagnostic evaluations.” In 2022, DaTscan was approved for use in individuals with suspected dementia with Lewy bodies.

In July 2021, aducanumab (Aduhelm™; Biogen), an amyloid beta-targeted antibody, was approved for the treatment of mild cognitive impairment or mild dementia due to Alzheimer disease. In July 2023, lecanemab-irmb (Leqembi®; Esai) received FDA approval as amyloid beta-targeted antibodies for the treatment of mild cognitive impairment or mild dementia due to Alzheimer disease. A third anti-amyloid antibody product, donanemab-azbt, was approved by the

FDA in July 2024. Aducanumab was subsequently discontinued by the manufacturer in 2024. The safety and efficacy of aducanumab, lecanemab, or donanemab in individuals with dementia with Lewy bodies has not been established as individuals with any medical or neurological condition other than Alzheimer disease that might be a contributing cause to the subject's cognitive impairment were excluded from trials. The use of DaT-SPECT for the diagnosis, management, or surveillance of Alzheimer disease is considered out of scope for this policy.

**BENEFIT APPLICATION:**

Coverage is subject to member’s specific benefits. Group-specific policy will supersede this policy when applicable.

**CURRENT CODING:**

**CPT Codes:**

78803	Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); tomographic (SPECT)
-------	--

**HCPCS Codes:**

A9584	Iodine I-123 ioflupane, diagnostic, per study dose, up to 5 millicuries
-------	---

**REFERENCES:**

1. Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. *Neurology*. Jul 29, 2014; 83(5):406-412.
2. American Academy of Neurology. *Neurology* 2006; 66(7):968-75. [Practice Guideline]. 2006/04/12. Available online at: [www.neurology.org/content/66/7/968.full.pdf](http://www.neurology.org/content/66/7/968.full.pdf).
3. Bajaj N, Hauser RA, Seibyl J, et al. Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN) in subjects with clinically uncertain parkinsonian syndromes. *Alzheimers Res Ther*. 2014; 6(5-8):67.
4. Bega D, Gonzalez-Latapi P, Zadikoff C, et al. Is There a Role for DAT-SPECT Imaging in a Specialty Movement Disorders Practice? *Neurodegener Dis*. 2015; 15(2):81-86.
5. Bega D, Kuo PH, Chalkidou A, et al. Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis. *NPJ Parkinsons Dis*. May 24, 2021; 7(1): 43.
6. Berardelli A, Wenning GK, Antonini A et al. EFNS/MDS-ES recommendations for the diagnosis of Parkinson’s disease. *Eur J Neurol* 2013; 20(1):16-34.
7. Berg D, Adler CH, Bloem BR, et al. Movement Disorder Society criteria for clinically established early Parkinson's disease. *Mov Disord*. Oct 2018; 33(10):1643-1646.



8. Bhatia KP, Bain P, Bajaj N, et al. Consensus Statement on the classification of tremors from the task force on tremor of the International Parkinson and Movement Disorder Society. *Mov Disord*. Jan 2018; 33(1): 75-87.
9. Booij J, Dubroff J, Pryma D, et al. Diagnostic performance of the visual reading of 123I-ioflupane SPECT images when assessed with or without quantification in patients with movement disorders or dementia. *J Nucl Med*. Nov 2017; 58(11):1821-1826.
10. Brigo F, Marinella A, Erro R et al. [(123I)FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: a meta-analysis. *Eur J Neurol* 2014.
11. Brigo F, Turri G, Tinazzi M. 123I-FP-CIT SPECT in the differential diagnosis between dementia with Lewy bodies and other dementias. *J Neurol Sci*. Dec 15, 2015; 359(1-2):161-171.
12. Burke RE, O'Malley K. Axon degeneration in Parkinson's disease. *Exp Neurol*. Aug 2013; 246:72-83.
13. Cardoso F, Goetz CG, Mestre TA, et al. A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease. *Mov Disord*. Feb 2024; 39(2): 259-266.
14. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. *Mov Disord* 2004; 19(10):1175-82.
15. Darcourt J, Booij J, Tatsch K et al. EANM procedure guidelines for brain neurotransmission SPECT using (123) I-labelled dopamine transporter ligands, version 2. *Eur J Nucl Med Mol Imaging* 2010; 37(2):443-50.
16. Djang DSW, Janssen MJR, Bohnen N. SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0. 2011. Available online at: [interactive.snm.org/docs/123I\\_ioflupane\\_SPECT\\_Practice\\_Guideline\\_JNM\\_Edit\\_FINAL.pdf](http://interactive.snm.org/docs/123I_ioflupane_SPECT_Practice_Guideline_JNM_Edit_FINAL.pdf).
17. Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. *Nat Rev Neurol*. Aug 2017; 13(8):457-476.
18. Erro R, Schneider SA, Stamelou M, et al. What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies. *J Neurol Neurosurg Psychiatry*. Mar 2016; 87(3):319-323.
19. Galvin JE. Improving the clinical detection of Lewy body dementia with the Lewy Body Composite Risk Score. *Alzheimers Dement (Amst)*. Sep 01, 2015; 1(3):316-324.
20. GE Healthcare. DaTscan Ioflupane I123 Injection Full Prescribing Information. 2015; [www.gehealthcare.com/en/products/categories/nuclear\\_imaging\\_agents/datscan](http://www.gehealthcare.com/en/products/categories/nuclear_imaging_agents/datscan).
21. Harvey HB, Watson LC, Subramaniam RM, et al. ACR Appropriateness Criteria Movement Disorders and Neurodegenerative Diseases. 2019; <https://acsearch.acr.org/docs/3111293/Narrative/>.
22. Hastings A, Cullinane P, Wrigley S, et al. Neuropathologic Validation and Diagnostic Accuracy of Presynaptic Dopaminergic Imaging in the Diagnosis of Parkinsonism. *Neurology*. Jun 11, 2024; 102(11): e209453.
23. Hauser RA, Bajaj N, Marek K, et al. Sensitivity, specificity, positive and negative predictive values and diagnostic accuracy of DaTscan (Ioflupane i123 injection): Predicting clinical diagnosis in early clinically uncertain parkinsonian syndrome. *J Neurol Stroke* 2014; 1(1)00003 //medcraveonline.com/JNSK/.

24. Hubburch M, Farmakis G, Schaefer A et al. FP-CIT SPECT does not predict the progression of motor symptoms in Parkinson's disease. *Eur Neurol* 2011; 65(4):187-92.
25. IOM (Institute of Medicine). 2011. *Clinical Practice Guidelines We Can Trust*. Washington, DC: The National Academies Press.
26. Jakobson Mo S, Linder J, Forsgren L, et al. Accuracy of visual assessment of dopamine transporter imaging in early parkinsonism. *Movement Disorders Clinical Practice*. 2015; 2(1):17-23.
27. Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. *J Neurol Neurosurg Psychiatry* 2010; 81(1):5-12.
28. Kemp PM, Clyde K, Holmes C. Impact of dopamine transporter SPECT using 123I-Ioflupane on the diagnosis and management of patients with dementia with Lewy bodies: a retrospective study. *Nucl Med Commun* 2011; 32(4):298-302.
29. Kupsch A, Bajaj N, Weiland F et al. Changes in Clinical Management and Diagnosis following DaTscan SPECT Imaging in Patients with Clinically Uncertain Parkinsonian Syndromes: A 12-Week Follow-Up Study. *Neurodegener Dis* 2013; 11(1):22-32.
30. Kupsch AR, Bajaj N, Weiland F et al. Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. *J Neurol Neurosurg Psychiatry* 2012; 83(6):620-8.
31. McCleery J, Morgan S, Bradley KM, et al. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. *Cochrane Database Syst Rev*. Jan 30, 2015.
32. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology*. Jul 04, 2017; 89(1):88-100.
33. Mo SJ, Linder J, Forsgren L, et al. Accuracy of visual assessment of dopamine transporter imaging in early parkinsonism. *Mov Disord Clin Pract*. 2015; 2(1):17-23.
34. Moonis G, Subramaniam RM, Trofimova A, et al. ACR Appropriateness Criteria Dementia. 2019; [acsearch.acr.org/docs/3111292/Narrative/](https://acsearch.acr.org/docs/3111292/Narrative/).
35. Morbelli S, Esposito G, Arbizu J, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. *Eur J Nucl Med Mol Imaging*. Jul 2020; 47(8): 1885-1912.
36. National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their careers [NG97]. 2018; <https://www.nice.org.uk/guidance/ng97>.
37. National Institute for Health and Care Excellence (NICE). Parkinson's disease in adults [NG71]. 2017; [www.nice.org.uk/guidance/NG71](http://www.nice.org.uk/guidance/NG71).
38. National Institute for Health and Care Excellence (NICE). Parkinson's disease in over 20s: diagnosis and management [CG35]. 2006; [www.nice.org.uk/guidance/cg35#diagnosing-parkinsons-disease](http://www.nice.org.uk/guidance/cg35#diagnosing-parkinsons-disease).
39. Nicastro N, Garibotto V, Allali G, et al. Added value of combined semi-quantitative and visual [123I]FP-CIT SPECT Analyses for the diagnosis of dementia with Lewy bodies. *Clin Nucl Med*. Feb 2017; 42(2):e96-e102.
40. Nicastro N, Garibotto V, Badoud S, et al. Scan without evidence of dopaminergic deficit: A 10-year retrospective study. *Parkinsonism Relat Disord*. Oct 2016; 31:53-58.

41. Nuvoli S, Spanu A, Piras MR, et al. 123I-ioflupane brain SPECT and 123I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders. *Medicine* (Baltimore). May 2017; 96(21):e6967.
42. O'Brien JT, Oertel WH, McKeith IG, et al. Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. *BMJ Open*. 2014; 4(7):e005122.
43. Oravivattanakul S, Benchaya L, Wu G, et al. Dopamine transporter (DaT) scan utilization in a movement disorder center. *Mov Disord Clin Pract*. 2015; 3(1):31-35.
44. Papathanasiou N, Rondogianni P, Chroni P et al. Interobserver variability, and visual and quantitative parameters of (123) I-FP-CIT SPECT (DaTSCAN) studies. *Ann Nucl Med* 2012; 26(3):234-40.
45. Papathanasiou ND, Boutsiadis A, Dickson J et al. Diagnostic accuracy of (1) (2) (3) I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. *Parkinsonism Relat Disord* 2012; 18(3):225-9.
46. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord*. Oct 2015; 30(12):1591-1601.
47. Prashanth R, Roy SD, Mandal PK, et al. High-accuracy classification of Parkinson's disease through shape analysis and surface fitting in 123I-Ioflupane SPECT imaging. *IEEE J Biomed Health Inform*. May 2017; 21(3):794-802.
48. Rizzo G, Copetti M, Arcuti S, et al. Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. *Neurology*. Feb 09, 2016; 86(6):566-576.
49. Rogers G, Davies D, Pink J, et al. Parkinson's disease: summary of updated NICE guidance. *BMJ*. Jul 27, 2017; 358:j1951.
50. Sadasivan S, Friedman JH. Experience with DaTscan at a tertiary referral center. *Parkinsonism Relat Disord*. Jan 2015; 21(1):42-45.
51. Seibyl JP, Kupsch A, Booij J, et al. Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using 123I-Ioflupane Injection (DaTscan) Imaging. *J Nucl Med*. Aug 2014; 55(8):1288-1296.
52. Seifert KD, Wiener JI. The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study. *Am J Neurodegener Dis*. 2013; 2(1):29-34.
53. Shimizu S, Namioka N, Hirose D, et al. Comparison of diagnostic utility of semi-quantitative analysis for DAT-SPECT for distinguishing DLB from AD. *J Neurol Sci*. Jun 15, 2017; 377:50-54.
54. Skanjeti A, Castellano G, Elia BO, et al. Multicenter semiquantitative evaluation of (123)I-FP-CIT brain SPECT. *J Neuroimaging*. Nov-Dec 2015; 25(6):1023-1029.
55. Suchowersky O, Reich S, Perlmutter J et al. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2006; 66(7):968-75. [Practice Guideline]. 2006/04/12. [www.neurology.org/content/66/7/968.full.pdf](http://www.neurology.org/content/66/7/968.full.pdf).
56. Thiriez C, Itti E, Fenelon G, et al. Clinical routine use of dopamine transporter imaging in 516 consecutive patients. *J Neurol*. Apr 2015; 262(4):909-915.
57. Thomas AJ, Attems J, Colloby SJ, et al. Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. *Neurology*. Jan 17, 2017; 88(3):276-283.

59. Tu XJ, Hwang WJ, Ma HI, et al. Determinants of generic and specific health-related quality of life in patients with Parkinson's disease. PLoS One. 2017; 12(6):e0178896.
60. Ueda J, Yoshimura H, Shimizu K, et al. Combined visual and semi-quantitative assessment of 123I-FP-CIT SPECT for the diagnosis of dopaminergic neurodegenerative diseases. Neurol Sci. Jul 2017; 38(7):1187-1191.
61. van der Zande JJ, Booij J, Scheltens P, et al. [(123)I] FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. Jun 2016; 43(6):1060-1066.
62. Vogt T, Kramer K, Gartenschlaeger M et al. Estimation of further disease progression of Parkinson's disease by dopamine transporter scan vs clinical rating. Parkinsonism Relat Disord 2011; 17(6):459-63.
63. Walker Z, Moreno E, Thomas A, et al. Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study. Br J Psychiatry. Feb 2015; 206(2):145-152.
64. Walker Z, Moreno E, Thomas A, et al. Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. Neurology. Sep 06, 2016; 87(10):1045-1051.
65. Wippold FJ, 2nd, Brown DC, Broderick DF, et al. ACR Appropriateness Criteria Dementia and Movement Disorders. J Am Coll Radiol. Jan 2015; 12(1):19-28.

## **POLICY HISTORY:**

Adopted for Blue Advantage, August 2012

Available for comment September 18 through October 31, 2012

Medical Policy Group, July 2013

Medical Policy Group, July 2014

Medical Policy Group, November 2015

Medical Policy Group, September 2016

Medical Policy Group, November 2017

Medical Policy Group, December 2018

Medical Policy Group, October 2019

Medical Policy Group, December 2019: Annual Coding Update

Medical Policy Group, October 2020

Medical Policy Group, November 2020

Medical Policy Group, October 2021

Medical Policy Group, October 2022

Medical Policy Group, November 2023

UM Committee, December 2023: Policy approved by UM Committee for use for Blue Advantage business.

Medical Policy Group, November 2024

UM Committee January 2025: Annual review of policy approved by UM Committee for use for Blue Advantage business.

---

*This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of*

*common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.*

*This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.*